Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Journey Medical Corp ( (DERM) ) is now available.
On September 25, 2025, Journey Medical Corporation amended its Credit Agreement with SWK Funding LLC, extending the maturity date of a $25 million term loan to June 27, 2028. The amendment also adjusted repayment terms, with principal repayments beginning in February 2026 unless the company’s revenue exceeds $60 million by the end of 2025, in which case repayments would start in February 2027.
The most recent analyst rating on (DERM) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Journey Medical Corp stock, see the DERM Stock Forecast page.
Spark’s Take on DERM Stock
According to Spark, TipRanks’ AI Analyst, DERM is a Neutral.
Journey Medical Corp’s overall stock score is primarily impacted by its financial challenges, including declining revenues and negative cash flows. Despite these issues, the successful launch of EMROSI and improved gross margins provide some positive momentum. Technical indicators suggest a bearish trend, and valuation metrics are unattractive due to ongoing losses. The earnings call highlights some positive developments, but these are tempered by increased expenses and a higher net loss.
To see Spark’s full report on DERM stock, click here.
More about Journey Medical Corp
Journey Medical Corporation operates in the medical industry, focusing on providing financial solutions and services. The company is involved in credit agreements and term loan facilities, catering to various financial institutions and stakeholders.
Average Trading Volume: 170,546
Technical Sentiment Signal: Buy
Current Market Cap: $189.4M
For a thorough assessment of DERM stock, go to TipRanks’ Stock Analysis page.